A proposed rule from the Office of Management and Budget (OMB) aims to expand political control over government research grants, potentially sidelining peer review and hindering scientific dissemination. Tens of thousands of researchers, doctors, and advocacy groups have submitted comments criticizing the plan, with nearly 100,000 submissions received by the July 13 deadline. A New York Times analysis of publicly posted comments indicated a strong majority oppose the rule, citing concerns that it shifts oversight from scientists to political appointees.

Critics argue the proposal could "catastrophically" and "devastatingly" impact medical progress. Concerns include the potential for political appointees to override expert peer review, turning grant allocation into a "pork-barrel project" rather than merit-based. This shift could jeopardize long-standing, successful research initiatives, from cancer therapies to vaccine development. Furthermore, proposed limitations on foreign collaboration and research into disparate impacts by race or sex could harm studies on pediatric, rare, and veteran health.

If finalized, the rule is expected to face legal challenges. The OMB has over a year to review comments and amend the draft. While some comments supported the rule, advocating for strengthened oversight and reduced waste, the overwhelming scientific community response signals significant opposition. This controversy could have lasting implications for the National Institutes of Health's funding mechanisms and the future direction of biomedical research in the U.S.